A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
Open Access
- 10 November 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (19), 5119-5125
- https://doi.org/10.1182/blood-2011-07-362475
Abstract
Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available afKeywords
This publication has 26 references indexed in Scilit:
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's LymphomaNew England Journal of Medicine, 2010
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaBritish Journal of Haematology, 2009
- Mechanism of action of lenalidomide in hematological malignanciesJournal of Hematology & Oncology, 2009
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Lenalidomide for the Treatment of B-Cell MalignanciesJournal of Clinical Oncology, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Immunobiology and Pathophysiology of Hodgkin LymphomasHematology-American Society Hematology Education Program, 2005
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002